Waldenstrom Macroglobulinemia clinical trials at UC Irvine
1 research study open to eligible people
open to eligible people ages 18 years and up
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.
Orange, California and other locations